Is Mounjaro Safe? What You Need to Know Before Starting Treatment
Yes, Mounjaro (tirzepatide) is considered safe for most adults when prescribed appropriately following a thorough clinical assessment. It is a licensed prescription medicine approved by the MHRA in the UK and has been studied in large-scale clinical trials involving tens of thousands of participants. Like all prescription medicines, it carries risks and is not suitable for everyone, which is why it must only be used under medical supervision.
How Mounjaro Works and Why the Assessment Matters
Mounjaro is a dual GIP and GLP-1 receptor agonist. It works by activating two hormone pathways involved in appetite regulation, slowing gastric emptying and reducing calorie intake over time. Because it affects hormonal and metabolic processes, a full clinical review before prescribing is not optional. It is the mechanism by which clinicians identify patients for whom the treatment is appropriate and those for whom it carries unacceptable risk.
At Colecross Pharmacy, every patient completes an initial consultation and health assessment before any prescription is issued. This includes a blood pressure check, weight and BMI recording, and a review of existing health conditions and medications. No treatment is dispensed through our weight loss service in Chelmsford without this process being completed in full.
MHRA Approval and Clinical Trial Evidence
Mounjaro was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the UK following a comprehensive review of clinical safety and efficacy data. The SURMOUNT clinical trial programme, which underpinned this approval, included participants across a wide range of ages, BMI levels, and health conditions. Serious adverse events were uncommon, and the benefit-risk profile was considered favourable for the approved indications.
NICE subsequently published guidance recommending Mounjaro for weight management through specialist NHS services (TA1026, 2024), a further indication that the treatment’s safety profile is considered acceptable by independent clinical bodies.
You can read more about how prescription medicines are assessed and regulated via the NHS medicines information pages.
Who Should Not Take Mounjaro
Mounjaro is not appropriate for all patients. Your clinician will use the assessment process to identify any contraindications. Treatment is generally not recommended for people who:
- → Have a personal or family history of medullary thyroid carcinoma (MTC)
- → Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- → Are pregnant, planning pregnancy, or breastfeeding
- → Have a history of severe gastrointestinal disease, including gastroparesis
- → Have had a serious hypersensitivity reaction to tirzepatide or any component of the product
- → Are under 18 years of age
This list is not exhaustive. Your prescribing clinician will review your full medical history and current medications to confirm whether Mounjaro is safe for you personally.
Common Side Effects and How They Are Managed
The most frequently reported side effects of Mounjaro are gastrointestinal in nature. These are well-documented, generally manageable, and tend to reduce in intensity as the body adjusts to treatment. The most common include:
Most commonly experienced during the first few weeks of treatment or following a dose increase. Eating smaller, lower-fat meals and avoiding lying down after eating can help reduce its severity.
Typically settles within a few weeks. Staying well hydrated and avoiding high-fibre foods during initial adjustment can help.
Can alternate with looser stools in some patients. Increasing fluid intake and gentle physical activity support gut motility during treatment.
More likely during the early stages or at higher doses. If persistent, your clinician may recommend staying at a lower dose for longer before escalating.
This is an intended effect of the treatment, but it is important not to under-eat to the point of nutritional deficiency. Guidance on maintaining adequate intake is provided as part of our clinical programme.
Serious but Rare Risks
While uncommon, there are more serious risks associated with Mounjaro that patients should be aware of. These include pancreatitis, gallbladder problems, and the thyroid-related concerns outlined in the contraindications section above. Patients should seek immediate medical attention if they experience severe and persistent abdominal pain, jaundice, or any signs of an allergic reaction, such as swelling of the face, throat, or difficulty breathing.
The gradual dose escalation structure built into the Mounjaro programme is specifically designed to reduce the likelihood of serious side effects by giving the body time to adjust at each stage. Your clinician will monitor your progress at follow-up appointments and can pause or stop treatment if any concerns arise.
Safety Monitoring During Treatment at Colecross Pharmacy
Safety does not end at the point of prescribing. Our clinical team provides ongoing monitoring throughout your treatment, including:
- ✓ Regular follow-up appointments to review progress and tolerability
- ✓ Blood pressure checks at each review
- ✓ Dose adjustments based on your individual response
- ✓ Clear guidance on what symptoms to report between appointments
- ✓ Access to clinical advice if concerns arise outside of scheduled reviews
Frequently Asked Questions: Is Mounjaro Safe?
Has Mounjaro been approved by UK regulators?
Yes. Mounjaro (tirzepatide) has been approved by the MHRA for use in the UK and has received NICE guidance for both type 2 diabetes (TA924) and weight management (TA1026). It has also been assessed by the European Medicines Agency (EMA). Regulatory approval requires extensive safety data before a medicine can be licensed.
Is Mounjaro safe for people with type 2 diabetes?
Mounjaro is licensed for use in adults with type 2 diabetes and has been studied extensively in this population. It can lower blood glucose levels, so patients on insulin or other diabetes medications may need their doses adjusted when starting Mounjaro. This must be managed by a clinician.
Can Mounjaro cause thyroid cancer?
Animal studies showed an increased risk of thyroid C-cell tumours with tirzepatide at high doses, which is why Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. To date, no causal link has been established in humans, but this remains a precautionary contraindication that all prescribers must screen for.
Is it safe to drink alcohol while taking Mounjaro?
There is no absolute contraindication between Mounjaro and alcohol, but alcohol can worsen gastrointestinal side effects such as nausea and may affect blood sugar levels, particularly in patients with diabetes. Moderation is advised and your clinician can provide personalised guidance during your consultation.
What should I do if I experience side effects on Mounjaro?
Mild gastrointestinal side effects are common and often settle with time. If symptoms are severe, persistent, or accompanied by abdominal pain, you should contact your prescribing clinician promptly. For any signs of a serious allergic reaction or severe abdominal pain, seek urgent medical attention. At Colecross Pharmacy, our clinical team is available to advise between appointments if concerns arise.
⚠ Important Disclaimer
This blog is intended as a general guide only and does not constitute personalised medical advice. Individual responses to Mounjaro can vary, and this information should not replace a consultation with a qualified healthcare professional. If you have specific concerns about side effects or your suitability for treatment, please get in touch with our team or speak to your GP.